About Nerio
Nerio is a Healthcare company based in La Jolla (United States) founded in 2019, and was acquired by Boehringer Ingelheim in July 2024. Technology for immunotherapy drug discovery is developed via high-throughput screening. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Nerio was founded in 2019 and is based in La Jolla, United States. Focus is placed on biotechnology for immuno-oncology applications. Small-molecule phosphatase inhibitors are created using high-throughput screening technologies and structure-guided chemistry. Drug discovery processes target immunotherapy advancements. Operations center on identifying and optimizing compounds for therapeutic use in oncology.
- Headquarters La Jolla, United States
- Stage Acquired
- SectorsHealthcare
- Website neriotx.com
- Acquired by Boehringer Ingelheim (Jul 2024)
- Investors
- Acquired byBoehringer Ingelheim
(Jul 2024)
Investors in Nerio
Nerio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Boehringer Ingelheim.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Generic drugs and clinical research services are provided globally. | 1885 | boehringer-ingelheim.com |
Investor details for Nerio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Nerio
2 dated milestones of Nerio across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Nerio is founded.
- Exit Acquired by Boehringer Ingelheim.
Competitors of Nerio
Nerio has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Nerio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Nerio (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Nerio
Nerio was founded in 2019.
Nerio is headquartered in La Jolla, United States. It is registered at La Jolla, California, United States.
Nerio was founded in 2019 and is based in La Jolla, United States. Focus is placed on biotechnology for immuno-oncology applications. Small-molecule phosphatase inhibitors are created using high-throughput screening technologies and structure-guided chemistry. Drug discovery processes target immunotherapy advancements. Operations center on identifying and optimizing compounds for therapeutic use in oncology.
Nerio has 1 investor. Key investors include Boehringer Ingelheim.
Yes. Nerio was acquired by Boehringer Ingelheim in July 2024.